This regulatory effect on inflammation not only has implications for metabolic diseases but also raises the possibility that GLP-1 receptor agonists could be harnessed as adjunct therapies to reduce cancer risk or progression, especially in inflammation-associated cancers such as colorectal and pancreatic carcinomas [35]. The gene discussed is GLP1R; the disease is metabolic disease.